Preclinical models revealed that combining 4-1BB agonism with PD-1 blockade reprograms terminally exhausted subsets, upregulates cytotoxic molecule expression, delays exhaustion progression, and suppresses tumor growth[224,225]. Here, PDCD1 is linked to neoplasm.